Sensor and digital technology advancements are opening new avenues for improving patient care and development efficiency. R&D executives are reacting to the need to boost innovation, increase profitability, and save costs. According to research conducted within the research centers of companies and university and federal laboratories, over 60% of new medical technologies have emerged from research conducted by start-ups, small to medium-sized firms (SMEs), and university spin-offs in the last decade. For large pharmaceutical and medical device companies, in-house R&D centers are also critical. The needs related to R&D have posed an existential challenge for MedTech R&D leaders, necessitating a new way of thinking, functioning, and conducting business. Many organizations are changing R&D efforts from core goods and line extensions toward transformational innovation, which generates and delivers customer value through novel products, solutions, and business models that answer unmet market demands and help build distinctive products. Moreover, various government funding tools are available in the continuously evolving medical device industry to preserve innovation and excellence. Governments play a vital role as performers and funders in domestic and international R&D efforts. The federal government has several responsibilities in the development and application of medical technology, such as the artificial heart. It funds technology-related research and development, regulates the investigational use of medical technology (drugs, biologics, and medical devices) on human beings, and authorizes the commercialization of goods that have been evaluated as safe and effective. The funding for R&D in PEP devices by companies and government is available in the OPEP devices market, and they are showing remarkable results, thus boosting the overall growth of the market.
With new features and advanced technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is
likely to drive the Middle East & Africa Oscillating positive expiratory pressure (OPEP) devices market at a notable CAGR during the forecast period.
Middle East & Africa Oscillating Positive Expiratory Pressure (OPEP) Devices Market Segmentation
The Middle East & Africa oscillating positive expiratory pressure (OPEP) devices market is segmented on the basis of product, indication, distribution channel, and country. Based on product, the market is segmented into mouthpiece PEP devices, face mask PEP devices, and bottle PEP devices. In 2021, the mouthpiece PEP devices segment accounted for the largest market share; and it is likely to register the highest CAGR during the forecast period. Based on indication, the market is categorized into chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiectasis, cystic fibrosis, and others. In 2021, the chronic obstructive pulmonary disease (COPD) segment accounted for the largest share of the market; however, the asthma segment is likely to register the highest CAGR during the forecast period. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2021, the hospital pharmacies segment held the largest market share; however, the retail pharmacies segment is expected to register the highest CAGR in the market during the forecast period. Further, based on country, the market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA. In 2021, South Africa held the largest market share, and Saudi Arabia is expected to register the highest CAGR during the forecast period.
Allergan Plc.; PARI GmbH; Smiths Medical; AirPhysio; Mercury Medical; and Medica Holdings, LLC are among some of the leading companies operating in the Middle East & Africa oscillating positive expiratory pressure (OPEP) devices market.